The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index; 21 of the 23 sources its claims cite were checked for support.
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
Open accessAbstract
The SARS-CoV-2 B.1.617 lineage was identified in October 2020 in India 1-5. Since then, it has become dominant in some regions of India and in the UK, and has spread to many other countries 6. The lineage includes three main subtypes (B1.617.1, B.1.617.2 and B.1.617.3), which contain diverse mutations in the N-terminal domain (NTD) and the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein that may increase the immune evasion potential of these variants. B.1.617.2-also termed the Delta variant-is believed to spread faster than other variants. Here we isolated an infectious strain of the Delta variant from an individual with COVID-19 who had returned to France from India. We examined the sensitivity of this strain to monoclonal antibodies and to antibodies present in sera from individuals who had recovered from COVID-19 (hereafter referred to as convalescent individuals) or who had received a COVID-19 vaccine, and then compared this strain with other strains of SARS-CoV-2. The Delta variant was resistant to neutralization by some anti-NTD and anti-RBD monoclonal antibodies, including bamlanivimab, and these antibodies showed impaired binding to the spike protein. Sera collected from convalescent individuals up to 12 months after the onset of symptoms were fourfold less potent against the Delta variant relative to the Alpha variant (B.1.1.7). Sera from individuals who had received one dose of the Pfizer or the AstraZeneca vaccine had a barely discernible inhibitory effect on the Delta variant. Administration of two doses of the vaccine generated a neutralizing response in 95% of individuals, with titres three- to fivefold lower against the Delta variant than against the Alpha variant. Thus, the spread of the Delta variant is associated with an escape from antibodies that target non-RBD and RBD epitopes of the spike protein.
Overview
CoChat Summary
## TL;DR
This study isolates an infectious SARS-CoV-2 Delta (B.1.617.2) virus and shows that it is less sensitive to neutralization by some monoclonal antibodies and by sera from convalescent or vaccinated individuals. Two vaccine doses restored strong neutralization, but Delta remained about 3- to 5-fold less sensitive than Alpha to vaccine-induced antibodies.
## Key findings
- The Delta isolate contained eight spike mutations relative to D614G: T19R, G142D, Δ156-157, R158G, L452R, T478K, P681R, and D950N.
- Among therapeutic monoclonal antibodies, bamlanivimab lost activity against Delta, while etesevimab, casirivimab, and imdevimab remained active; Delta was also resistant to some anti-RBD and anti-NTD antibodies.
- In convalescent sera, Delta neutralization was fourfold lower than Alpha at month 12 in the Strasbourg cohort, and in the Orléans cohort Delta titers were four- to sixfold lower than Alpha and D614G, respectively.
- After vaccination, a single dose gave weak neutralization: only 13% of Pfizer sera neutralized Delta after one dose, and only 4% and 9% of AstraZeneca sera neutralized Beta and Delta, respectively; after two doses, neutralizing responses rose to 95–100% of individuals for the tested strains.
## Methods
- The authors isolated an infectious Delta variant from a nasopharyngeal swab of a symptomatic traveler returning from India, amplified it on Vero E6 cells, and compared it with D614G, Alpha, and Beta viruses.
- They tested monoclonal antibodies and sera from human cohorts: 56 convalescent individuals from Orléans, 47 convalescent individuals from Strasbourg at month 12, and 59 vaccinated individuals (16 Pfizer, 43 AstraZeneca), using the S-Fuse neutralization assay and flow cytometry binding assays.
- Main analyses included ED50/IC50 neutralization comparisons and group tests reported as Friedman with Dunn’s multiple comparisons and Kruskal-Wallis with Dunn’s multiple comparisons.
## Limitations
- The paper explicitly states a low number of vaccinated individuals analyzed and no characterization of cellular immunity.
- The study also states that the work is observational/exploratory, with no randomization and no blinding; this is a design limitation evident from the Methods and reporting summary.
- Sample-size planning was not performed a priori: the paper says no statistical methods were used to predetermine sample size.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
17 Valid · 1 Not valid · 2 Not checked · 80 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“We tested four clinically approved monoclonal antibodies that target the RBD 18,19 (bamlanivimab (LY-CoV555), etesevimab (LY-CoV016), casirivimab (REGN10933) and imdevimab (REGN10987))”
What the sources say
- Partly supportedcites [18] Taylor, P. C. et al. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat. Rev. Immunol. 21, 382–393 (2021). sourceExperimental — accuracy not yet measured
Figure 3 in “Monoclonal antibodies for COVID-19” identifies all four antibodies as binding the RBD. The Introduction says their three treatment regimens had emergency use authorization, not full clinical approval; the claim overstates their regulatory status. (LLM, conf=0.86)
- Partly supportedcites [19] Starr, T. N. et al. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. Science 371, 850–854 (2021). sourceExperimental — accuracy not yet measured
The paper’s main-text passage (indexed under Abstract; page unavailable) identifies REGN10933, REGN10987 and LY-CoV016 as antibodies targeting the RBD. It does not identify bamlanivimab (LY-CoV555), and it says the REGN-COV2 cocktail had emergency use authorization while LY-CoV016 was in phase 3 trials. It therefore does not support the claim that all four named antibodies were clinically approved. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“These altered residues are found in the NTD 'supersite' that is targeted by most anti-NTD neutralizing antibodies 15 .”
What the sources say
- Supportedcites [15] McCallum, M. et al. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. Cell 184, 2332–2347 (2021). source
The Results section on NTD-specific neutralizing mAbs defines the supersite by its residue ranges, and the antigenic-map section reports that all potently neutralizing mAbs in the authors’ panel targeted overlapping epitopes there. The section on NTD variants also identifies altered residues within the supersite. The citing sentence does not specify which altered residues it means, so their individual locations cannot be checked. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This mutation is close to the E484K mutation that facilitates antibody escape 13 .”
What the sources say
- Partly supportedcites [13] Plante, J. A. et al. The variant gambit: COVID-19’s next move. Cell Host Microbe 29, 508–515 (2021). sourceExperimental — accuracy not yet measured
The “RBD variant changes” section associates E484K with immune escape from monoclonal antibodies and polyclonal sera. It does not mention T478K or establish that T478K is close to E484K (searched: T478K, residue 478, and proximity to E484K). (LLM, conf=0.85)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Bamlanivimab lost antiviral activity against the Delta variant, in line with previous results that showed that L452R is an escape mutation for this antibody 16 .”
What the sources say
- Supportedcites [16] Starr, T. N., Greaney, A. J., Dingens, A. S. & Bloom, J. D. Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016. Cell Rep. Med. 2, 100255 (2021). source
The citation supports the sentence’s reference to previous results showing that L452R escapes bamlanivimab, rather than its own observation about the Delta variant. The Results identify L452R as an escape mutation for LY-CoV555 (bamlanivimab), and the Discussion’s limitations section reports that the FDA subsequently confirmed loss of neutralization with L452R. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Levels of neutralizing antibodies are highly predictive of immune protection from symptomatic SARS-CoV-2 infection 25 .”
What the sources say
- Supportedcites [25] Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. (2021). source
The paper’s title (p. 1) states the claim directly. Its opening summary (p. 1) says that neutralization level is highly predictive of immune protection, and the Discussion (p. 6) identifies neutralizing antibodies as an immune correlate of protection. (LLM, conf=0.95)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
39 more claims · 2 with their cited sources checked
Create a free account to see all 100 claims and every source verdict.
- It may state two separate claims as one. 34
- Probably not a substantial claim. 31
- The quote only partly states this claim. 7
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of plasma samples from persons receiving the AZD1222 vaccine, 42% had 3-fold to 10-fold and 54% had >10-fold reduced Beta variant neutralizing activity 104,214,224 (fIg.5).”
From The biological and clinical significance of emerging SARS-CoV-2 variants (2021) · cites this paper as [214]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among plasma samples obtained from recipients of the BNT162b vaccine, approximately 15% displayed 3-fold to 10-fold reduced neutralizing activity against the Delta variant 100,118,214 (fIg.5).”
From The biological and clinical significance of emerging SARS-CoV-2 variants (2021) · cites this paper as [214]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“By contrast, among plasma samples obtained from recipients of the AZD1222 vaccine, higher proportions displayed reduced neutralizing activity against this variant 100,209,214 .”
From The biological and clinical significance of emerging SARS-CoV-2 variants (2021) · cites this paper as [214]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It results in approximately 3-fold to 10-fold reduced susceptibility to 45% and >10-fold reduced susceptibility to 5% of convalescent plasma samples 100,118,214,215,231 (fIg.5).”
From The biological and clinical significance of emerging SARS-CoV-2 variants (2021) · cites this paper as [214]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many such variants, including Delta and the most recent Omicron, have adopted different mutation strategies to evade immune recognition, leading to the failure of neutralizing antibodies and vaccines (18, 23, 45–48).”
From Deep learning guided optimization of human antibody against SARS-CoV-2 variants with broad neutralization (2022) · cites this paper as [23]
Experimental — accuracy not yet measured
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
Korber, B., Fischer, W. M., Gnanakaran, S., Yoon, H., Theiler, J., Abfalterer, W., Hengartner, N., Giorgi, E. E., Bhattacharya, T., Foley, B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.043 · Cited by 4,281
Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021) · Nature Medicine · doi:10.1038/s41591-021-01377-8 · Cited by 3,742
Nextstrain: real-time tracking of pathogen evolutionPreprint
Hadfield, J., Megill, C., Bell, S. M., et al. (2017) · bioRxiv · doi:10.1101/224048 · Cited by 3,172
Nextstrain: real-time tracking of pathogen evolution
Hadfield, J., Megill, C., Bell, S. M., Huddleston, J., Potter, B., Callender, C., Sagulenko, P., Bedford, T., & Neher, R. A. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty407 · Cited by 3,154
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
Lopez Bernal, J., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108891 · Cited by 2,889
Effectiveness of COVID-19 vaccines against the B.1.617.2 variant
Bernal, J. L., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., et al. (2021) · doi:10.1101/2021.05.22.21257658 · Cited by 2,888
A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology
Rambaut, A., Holmes, E. C., O’Toole, Á., Hill, V., McCrone, J. T., Ruis, C., du Plessis, L., & Pybus, O. G. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0770-5 · Cited by 2,543
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
Wang, P., Nair, M. S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P. D., et al. (2021) · Nature · doi:10.1038/s41586-021-03398-2 · Cited by 2,312
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
Barnes, C. O., Jette, C. A., Abernathy, M. E., Dam, K.-M. A., Esswein, S. R., Gristick, H. B., Malyutin, A. G., Sharaf, N. G., Huey-Tubman, K. E., Lee, Y. E., et al. (2020) · Nature · doi:10.1038/s41586-020-2852-1 · Cited by 1,599
Cited by
Mechanisms of SARS-CoV-2 entry into cells
Jackson, C. B., Farzan, M., Chen, B., & Choe, H. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00418-x · Cited by 3,022
Considerable escape of SARS-CoV-2 Omicron to antibody neutralization
Planas, D., Saunders, N., Maes, P., Guivel-Benhassine, F., Planchais, C., Buchrieser, J., Bolland, W.-H., Porrot, F., Staropoli, I., Lemoine, F., et al. (2022) · Nature · doi:10.1038/s41586-021-04389-z · Cited by 1,514
Self-citationmRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant
Garcia-Beltran, W. F., St. Denis, K. J., Hoelzemer, A., Lam, E. C., Nitido, A. D., Sheehan, M. L., Berrios, C., Ofoman, O., Chang, C. C., Hauser, B. M., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.033 · Cited by 1,045
“Neutralization of Delta variant pseudovirus was decreased relative to wild type for all subgroups ( Figure 2C ), as has been previously reported (Mlcochova et al., 2021; Planas et al., 2021).”
ResultIncreased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa
Pulliam, J. R. C., van Schalkwyk, C., Govender, N., Gottberg, A. V., Cohen, C., Groome, M. J., Dushoff, J., Mlisana, K., & Moultrie, H. (2021) · doi:10.1101/2021.11.11.21266068 · Cited by 1,037
“Finally, sera obtained from individuals after both one and two doses of the BNT162b2 (Pfizer) or ChAdOx1 (AstraZeneca) vaccines displayed lower neutralization of the Beta and Delta variants compared with non-VOCs and the Alpha VOC (9).”
The biological and clinical significance of emerging SARS-CoV-2 variants
Tao, K., Tzou, P. L., Nouhin, J., Gupta, R. K., de Oliveira, T., Kosakovsky Pond, S. L., Fera, D., & Shafer, R. W. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00408-x · Cited by 1,009
Metadata
- Authors
- Planas, D., Veyer, D., Baidaliuk, A., Staropoli, I., Guivel-Benhassine, F., Rajah, M. M., Planchais, C., Porrot, F., Robillard, N., Puech, J., Prot, M., Gallais, F., Gantner, P., Velay, A., Le Guen, J., Kassis-Chikhani, N., Edriss, D., Belec, L., Seve, A., Courtellemont, L., Péré, H., Hocqueloux, L., Fafi-Kremer, S., Prazuck, T., Mouquet, H., Bruel, T., Simon-Lorière, E., Rey, F. A., & Schwartz, O.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Institut Pasteur (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Centre hospitalier universitaire d'Orléans (FR)
- Corresponding author
- Bruel, Timothée
- Schwartz, Olivier
- ORCID
- Planas, Delphine
- Veyer, David
- Baidaliuk, Artem
- Staropoli, Isabelle
- Rajah, Maaran Michael
- Planchais, Cyril
- Porrot, Françoise
- Puech, Julien
- Prot, Matthieu
- Gallais, Floriane
- Gantner, Pierre
- Velay, Aurélie
- Péré, Hélène
- Hocqueloux, Laurent
- Mouquet, Hugo
- Bruel, Timothée
- Simon-Lorière, Etienne
- Rey, Felix A.
- Schwartz, Olivier
- Venue
- Nature
- Published
- 2021-07-08
- Volume
- 596
- Issue
- 7871
- Pages
- 276-280
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W3182094313
- Cited by
- 1,992
- References
- 38
- Citations by year
- 2026: 43 · 2025: 91 · 2024: 156 · 2023: 315 · 2022: 935 · 2021: 449
- FWCI
- 146.93
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Agence Nationale de la Recherche (PROTEO-SARS-CoV-2, ANR-10–INSB–04, ANR-10-LABX-77, 2017-, 10-LABX-62-IBEID, ANR-11-LABX-0070, ANR-10–INSB–04-01, 10-INSB-04-01, ANR‐10‐LABX‐62‐IBEID, ANR‐10‐LABX‐69‐01, LABX-62-IBEID, ANR-21-CO14-0007, DIM1Health, 10‐LABX‐69‐01, ANR18, ANR-10-LABX-0069, UMR_S 1109, ANR-10-LABX-0077, ANR-10, ANR-10-LABX, ANR-18-CE17-0028, ANR-10-LABX-0062, ANR-10-INBS-0004, ANR-10-LABX-62)
- Institut National de la Santé et de la Recherche Médicale (UMR_S 1109, ANR-10-INSB-04-01, ANR-10-LABX-77, ANR-10-LABX-62-IBEID)
- Fondation pour la Recherche Médicale (ANR-10-LABX-62-IBEID, PROTEO-SARS-CoV-2, ANR-10-LABX-77)
- Conseil Régional, Île-de-France (DIM 1Health)
- Fondation de France (#00106077)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
- Keywords
- Delta variant, B.1.617, antibody neutralization, immune evasion, receptor binding domain, monoclonal antibodies, bamlanivimab, convalescent sera, COVID-19 vaccines, Alpha variant, spike protein mutations
- MeSH terms
- COVID-19, COVID-19 Vaccines, Antibodies, Viral, Epitopes, Convalescence, France, Humans, India, Male, Middle Aged, Neutralization Tests, Immune Evasion, Antibodies, Neutralizing, Antibodies, Monoclonal, Humanized, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. https://app.cochat.ai/papers/10.1038/s41586-021-03777-9
- The paper
- Planas, D., Veyer, D., Baidaliuk, A., Staropoli, I., Guivel-Benhassine, F., Rajah, M. M., Planchais, C., Porrot, F., Robillard, N., Puech, J., Prot, M., Gallais, F., Gantner, P., Velay, A., Le Guen, J., Kassis-Chikhani, N., Edriss, D., Belec, L., Seve, A., . . . Schwartz, O. (2021). Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. https://doi.org/10.1038/s41586-021-03777-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.